The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mallela Venkataramana Reddy
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
BSE has received a disclosure under SEBI's Takeover Regulations from Mallela Venkataramana Reddy, an individual shareholder/promoter of Novelix Pharmaceuticals Ltd. Regulation 29(1) filings are triggered when an acquirer crosses the 5% shareholding threshold or changes their holding by 2% or more. The specific direction of the transaction (acquisition or sale), the number of shares, and the resulting shareholding percentage are not mentioned in the headline. The disclosure is a routine regulatory compliance step required under SEBI's substantial acquisition norms.
The filing itself is a procedural disclosure and does not directly indicate a major shift in ownership. Shareholders should look for the detailed disclosure to understand whether this is an acquisition or sale and assess any potential impact on promoter holding or takeover implications.